Delivery Order SPE2DB20D2001-SPE2DB25FPNJX
- Not listed
- The U.S. Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalation powder (60-dose units), with a ceiling value of $3,023.81. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement. The order is set for ultimate completion by August 19, 2025, and will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $4,665.23 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Trelegy Ellipta 100-62.5-25, a combination inhalation powder used in the treatment of chronic obstructive pulmonary disease. This non-competitive delivery order represents a firm fixed price transaction with a completion date of August 12, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $3,931.56 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalation powder (60-count package), with completion targeted for August 25, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December...
- The Defense Logistics Agency awarded a delivery order valued at $1,671.43 to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalation powder in a 60-dose configuration. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of August 22, 2025. The award is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $31,540.49 delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of May 13, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order valued at $3,279.40 to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Trelegy Ellipta 200-62.5-25, a combination inhalation powder medication used in respiratory disease management. This firm fixed-price, non-set-aside delivery order is scheduled for completion by September 19, 2025, with performance taking place at the vendor's corporate office in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalation powder in a 60-dose configuration, with a ceiling value of $14,067.25. This is a firm fixed price delivery order with no set-aside designation, reflecting competitive procurement. The order is scheduled for ultimate completion by July 29, 2025, with performance to occur at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $21,853.31 to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalation powder in 60-dose units. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 7, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order valued at $21,488.46 to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count package). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of July 30, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate office and serves as a major...
- The Defense Logistics Agency awarded a $13,636.14 delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalation powder in 60-dose units. This is a firm fixed price, non-set-aside contract with a completion date of August 6, 2025, and performance to be fulfilled at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite...
- SPE2DB20D2001Indefinite Delivery Contract
- SPE2DB20D2001-SPE2DB25FPNJXDelivery Order
The Defense Logistics Agency awarded a $21,179.80 delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalation powder in 60-dose units. This firm fixed-price delivery order is scheduled for completion by August 7, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The contract was competitively awarded without set-aside restrictions, reflecting AmerisourceBergen's qualification to compete for federal pharmaceutical procurement through open competition. This delivery order represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Trelegy Ellipta is a combination respiratory therapy medication used in the treatment of chronic obstructive pulmonary disease and asthma, consistent with the company's portfolio of specialty medications and brand-name pharmaceuticals supplied through its federal contract awards to the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.2k | 8/6/25 |